Merrimack Pharmaceuticals is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.
Merrimack first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in Europe the following year.
Merrimack was founded by a group of scientists from MIT and Harvard University in 2000.
In 2016, Merrimack had 426 full-time employees, 103 of which had an MD or PhD.
In October 2016, CEO Robert Mulroy resigned and the company announced they would be laying off 20% of its employees. In January 2017, interim CEO Gary Crocker resigned and the board of directors appointed Richard Peters to be president and CEO. Peters previously worked at Sanofi and was a faculty member at Harvard University.
In January 2017, French pharmaceutical company Ipsen announced they would be purchasing Onivyde from Merrimack for approximately $1 billion.
Merrimack has four drugs in clinical development.